Progress in medicine often begins at the fringes, with ideas dismissed as dangerous or absurd, and people willing to advance them anyway.
- Washing your hands was once radical. Ignaz Semmelweis was mocked for claiming doctors spread infection through touch.
- Antibiotics were dismissed. Alexander Fleming’s discovery of penicillin was untrusted and ignored for years.
- The microbiome was pseudoscience. When researchers launched the Human Microbiome Project in the 2000s, critics called it “scientific astrology.”
History shows us that medicine moves forward when we look closer, think differently, and say what others won’t.
And if I had to place my bet on the next major paradigm shift in human health, it’s peptides.
Peptides extend what medicine can do.
Contrary to what most think, peptides aren’t new, and they aren’t born out of a lab.
The human body produces thousands of peptides, including familiar names like insulin, creatine, and collagen. These short chains of amino acids act as messengers, instructing cells what to do.
Over the last century, scientists have discovered ways to refine peptide signals, creating analogs that target specific pathways in the body. The most famous example: Ozempic, a GLP-1 receptor agonist.
And while GLP-1s put peptides on the map, they’re one peptide of hundreds. Peptides impact nearly every biological system, from inflammation and immunity to fertility, recovery, and cognition. Name a function, and there’s a peptide that influences it.
The next wave of peptide therapies will change how we heal, age, perform, and live.
So what’s holding us back?
If peptides have so much potential, why aren’t they everywhere?
Peptides seem incredibly promising, yet most aren’t FDA-approved. Why? The reason is less about science and more about incentives.
FDA approval requires multi-phase clinical trials that can cost tens of millions. Pharmaceutical companies bankroll these trials when they can patent a molecule and make money.
However, many peptides cannot be patented because they are naturally occurring (or closely resemble nature). That makes them commercially unattractive. Peptides that are FDA-approved typically exist as modified or synthetic analogs (e.g., GLP-1 agonists). Slight structural tweaks create patentability, manufacturability, and margins.
With no clear model for monetizing unmodified, naturally-occurring peptides, Big Pharma interest dries up.
And yet, public interest keeps climbing.
When science outpaces regulation, people experiment.
As demand grows and research lags, a parallel market for peptides has taken shape around the world … and in the US.
In countries like Russia, peptides such as Epitalon and Thymogen have been used for decades. In Italy, China, and Australia, peptides appear in sports medicine, rehabilitation, and hospital protocols.
Yet the US remains unregulated. Here, many peptides exist in a gray zone, sold for “research use only” and distributed through private longevity clinics.
But athletes, biohackers, and billionaires are not waiting.
Each week I have dozens of people messaging me asking to get them peptides. I’ve personally tested over 20 different peptides and take a handful weekly. Most of the elite concierge doctors I know procure peptides for their patients. And yet, with promise comes risk.
With undeniable promise comes undoubtable risk.
Peptides hold undeniable promise. In both controlled studies and real-world use, a consistent story emerges: peptides drive measurable effects across core systems, from cognition to wound healing.
I predict that over the next decade, we’ll see peptides become as familiar insulin, creatine, or collagen. We’ll trade a morning caffeine spike for a GLP-1 micro-dose, swap ice baths for BPC-157, and retinol for GHK-CU.
And yet, as with anything new, peptides hold undeniable risk. Doses vary, untested compounds emerge, and low purity supply chains creep in. We’ll need more robust regulation before mainstream adoption.
The future of medicine isn’t waiting for permission.
Over the past two days, I have received hundreds of messages asking about peptides. The hype is unprecedented. And yet the debate is still between two extremes.
On one end sensationalized, hyperbolic headlines and social media claims about “Wolverine drugs” and “miracle molecules.” On the other, a growing cynicism that assumes if something isn’t FDA approved, it must be dangerous by default.
We reject both.
We hold a third position: rigorous, open minded inquiry.
The absence of large studies and FDA approval is not the absence of truth. It’s an opportunity to ask questions, observe, build hypotheses, and test.
The next chapter of human health doesn’t come from close minded consensus seeking. It comes from open minded truth seeking.
And we intend to do just that. We’ll map this space through exploration and evidence, running controlled experiments, interrogating every claim, and separating data from dogma.
Because progress doesn’t wait for permission. And neither do we.